Biomedicine Daily · Sunday, 27 September 2026
CBA FRONTIER INSIGHTS
FDA Approves AbbVie's Tavapadon for Parkinson's Disease
The FDA has approved AbbVie's tavapadon, a next-generation dopamine therapy for Parkinson's disease designed to deliver symptom relief comparable to earlier dopamine-based treatments with fewer side effects. Details on dosing, launch timing, and pricing were not disclosed, but the approval gives clinicians a new option in a therapeutic class where tolerability has long constrained care. The decision headlined a day that also brought a rare Trump administration move to claw back nearly $1 billion in congressionally approved spending, mostly HHS programs serving refugees and unaccompanied minors, alongside new human evidence linking the gut-derived metabolite indole-3-propionic acid to type 2 diabetes risk and glycemic variability.
Regulatory and policy
AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval
The FDA has approved AbbVie's tavapadon, a next-generation therapy for Parkinson's disease designed to provide symptom relief comparable to its predecessors with fewer side effects. No further details on dosing, launch timing or pricing were available. The approval gives Parkinson's clinicians a new dopamine-based treatment option.
Trump administration uses rare authority to claw back nearly $1B in spending approved by Congress
President Donald Trump is canceling nearly $1 billion in spending approved by Congress, mostly HHS programs serving refugees and unaccompanied minors, using a contested "pocket rescission" announced with five days left in the fiscal year. The cuts also include $70 million for international education programs, $28 million for HHS research grants, and $10 million from a minority business development program. Congress has 45 days to review the proposal, and Sen. Susan Collins has vowed to challenge what she calls illegal impoundment.
Research papers
doi.orgPlasma indole-3-propionic acid is a gut-derived metabolite and is associated with type 2 diabetes and cardiometabolic outcomes: Evidence from a human antibiotic intervention
Plasma indole-3-propionic acid (IPA) is lower in individuals with type 2 diabetes than in healthy controls, and higher pre-antibiotic levels associate with reduced T2D odds. In both groups, 7-day broad-spectrum antibiotic treatment reduced IPA to near-undetectable levels, confirming its predominantly microbial origin. IPA also showed a novel inverse correlation with glycemic variability and linked to gut microbiota beta diversity rather than known IPA-producing taxa alone.
Plasma indole-3-propionic acid is a gut-derived metabolite and is associated with type 2 diabetes and cardiometabolic outcomes: Evidence from a human antibiotic intervention
Plasma indole-3-propionic acid (IPA) is lower in people with type 2 diabetes than in healthy controls and higher levels are associated with reduced T2D odds. A 7-day broad-spectrum antibiotic intervention, which suppressed gut microbiota in individuals given histidine supplementation, cut IPA to near-undetectable levels in both groups, confirming its microbial origin. IPA also showed a novel inverse correlation with glycemic variability, and was associated with gut microbiota beta diversity rather than any known IPA-producing taxa.
Assessing the consistency of overall survival extrapolations in Swedish health technology assessment reports of oncology treatments using extended follow-up data
Overall survival extrapolations in Swedish TLV oncology appraisals were frequently conservative: reapplying original assumptions to longer follow-up data raised the average area under the curve of extrapolated OS by 8.8% (95% CI 5.2% to 12.6%) under TLV assumptions and by 10.9% (95% CI 6.9% to 15.1%) under manufacturer assumptions. The findings argue for revisiting survival model fit and treatment-waning assumptions when longer-term data become available.
doi.orgAssessing the consistency of overall survival extrapolations in Swedish health technology assessment reports of oncology treatments using extended follow-up data
Overall survival extrapolations in Swedish TLV oncology appraisals from 2009 to 2019 were often conservative for the active arm. Reapplying the original extrapolation assumptions to longer follow-up data (average 54.2 months versus 28.1 months originally) raised the average area under the survival curve by 8.8% under TLV assumptions and 10.9% under manufacturer assumptions, with material increases above 10% in roughly one-third of cases. The findings argue for revisiting survival model fit and assumptions as longer-term data emerge.
Methods and resources
Discrepancies between ChIP-seq and CUT&Tag histone mark profiles are explained by GC content and chromatin accessibility
Systematic comparison of ChIP-seq and CUT&Tag histone mark profiles in K562 and MCF-7 cells shows that many disagreements between the assays track GC content and chromatin accessibility. CUT&Tag loses H3K36me3 signal in GC-poor active gene bodies and H3K27me3 signal in GC-poor Polycomb-repressed domains, and promoters with discrepant H3K4me3 and H3K27ac signal differ systematically in GC content and DNase-seq and ATAC-seq signal. Studies profiling histone modification intensity and structure should account for these biases.
SHERLOCK: Structured representation learning and causal inference of downstream perturbation effects
SHERLOCK is an interpretable deep generative framework that represents genetic, pharmacological, and experimental perturbations as structured interventions on a latent baseline cellular state within a structural causal model. It learns correlated and sparse perturbation representations, organizes perturbations by shared transcriptional responses, and supports counterfactual estimation of downstream transcriptional effects, condition-dependent response analysis, and compositional modeling of combinatorial perturbations. Across genome-scale CRISPR, chemical, and spatial perturbation datasets, it recovers perturbation relationships concordant with known pathways and pharmacological properties and predicts held-out perturbation combinations.
Also today
1 events that did not make today's daily, one table per category, one row per event. Open a category to expand.